Keyword: Intercept Pharmaceuticals

Intercept jumps on NASH phase 3 protocol changes

Intercept was down 12% premarket this morning as it announced an out-of-the-blue update on its late-stage fatty liver disease test, but jumped first thing after changing its endpoints and the definition of NASH improvement for its study.